SEC Form 4 · accession 0001437749-26-023290
UroGen Pharma Ltd. · URGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Schoenberg
Officer — Chief Medical Officer
Period of report
Jul 9, 2026
Accepted (ET)
Jul 10, 2026 · 2:17 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001668243
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF2 | Jul 9, 2026 | S | 10,000 | $40.00 | D | 119,763 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to a duly adopted trading plan under Rule 10b5-1(c). The adoption date of the referenced Rule 10b5-1(c) plan is August 15, 2025. This transaction represents the final sale under such trading plan.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 and $40.02. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.